Biomarkers in the Pathogenesis, Diagnosis, and Treatment of Systemic Sclerosis

References

• Khanna D, Tashkin DP, Denton CP, Renzoni EA, Desai SR, Varga J. Etiology, Risk Factors, and Biomarkers in Systemic Sclerosis with Interstitial Lung Disease. Am J Respir Crit Care Med. 2020;201(6):650–660. doi:10.1164/rccm.201903-0563CI
   PubMed Web of Science ®Google Scholar
• Kang EH, Ha YJ, Lee YJ. Autoantibody Biomarkers in Rheumatic Diseases. Int J Mol Sci. 2020;21(4):1382. doi:10.3390/ijms21041382
   PubMed Web of Science ®Google Scholar
• Ligon C, Hummers LK. Biomarkers in Scleroderma: progressing from Association to Clinical Utility. Curr Rheumatol Rep. 2016;18(3):17. doi:10.1007/s11926-016-0565-0
   PubMed Web of Science ®Google Scholar
• Graßhoff H, Fourlakis K, Comdühr S, Riemekasten G. Autoantibodies as Biomarker and Therapeutic Target in Systemic Sclerosis. Biomedicines. 2022;10(9):2150. doi:10.3390/biomedicines10092150
   PubMed Web of Science ®Google Scholar
• Chairta PP, Nicolaou P, Christodoulou K. Enriched in silico analysis of MS-based extracted candidate proteomic biomarkers highlights pathogenic pathways in systemic sclerosis. Sci Rep. 2023;13(1):1934. doi:10.1038/s41598-023-29054-5
   PubMed Web of Science ®Google Scholar
• Abignano G, Del Galdo F. Biomarkers as an opportunity to stratify for outcome in systemic sclerosis. Eur J Rheumatol. 2020;7(Suppl 3):S193–S202.
   PubMedGoogle Scholar
• Bălănescu P, Bălănescu A, Bălănescu E, Băicuş C. Candidate proteomic biomarkers in systemic sclerosis discovered using mass-spectrometry: an update of a systematic review (2014-2020). Rom J Intern Med. 2021;59(2):101–111. doi:10.2478/rjim-2020-0037
   PubMed Web of Science ®Google Scholar
• Utsunomiya A, Oyama N, Hasegawa M. Potential Biomarkers in Systemic Sclerosis: a Literature Review and Update. J Clin Med. 2020;9(11):3388. doi:10.3390/jcm9113388
   PubMed Web of Science ®Google Scholar
• Wermuth PJ, Piera-Velazquez S, Jimenez SA. Identification of novel systemic sclerosis biomarkers employing aptamer proteomic analysis. Rheumatology. 2018;57(10):1698–1706. doi:10.1093/rheumatology/kex404
   PubMed Web of Science ®Google Scholar
• Bălănescu P, Bălănescu E, Băicuș C, Bălănescu A. Circulatory cytokeratin 17, marginal zone B1 protein and leucine-rich α2-glycoprotein-1 as biomarkers for disease severity and fibrosis in systemic sclerosis patients. Biochem Med (Zagreb). 2022;32(3):030707. doi:10.11613/BM.2022.030707
   PubMed Web of Science ®Google Scholar
• Gigante A, Navarini L, Margiotta D, et al. Angiogenic and angiostatic factors in renal scleroderma-associated vasculopathy. Microvasc Res. 2017;114:41–45. doi:10.1016/j.mvr.2017.06.003
   PubMed Web of Science ®Google Scholar
• Mostmans Y, Cutolo M, Giddelo C, et al. The role of endothelial cells in the vasculopathy of systemic sclerosis: a systematic review. Autoimmun Rev. 2017;16(8):774–786. doi:10.1016/j.autrev.2017.05.024
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhu M, Xie L, Zhang H, Deng T. Identification and validation of key immune-related genes with promising diagnostic and predictive value in systemic sclerosis. Life Sci. 2023;312:121238. doi:10.1016/j.lfs.2022.121238
   PubMed Web of Science ®Google Scholar
• Kania G, Rudnik M, Distler O. Involvement of the myeloid cell compartment in fibrogenesis and systemic sclerosis. Nat Rev Rheumatol. 2019;15(5):288–302. doi:10.1038/s41584-019-0212-z
   PubMed Web of Science ®Google Scholar
• Denton CP, Khanna D. Systemic sclerosis. Lancet. 2017;390(10103):1685–1699. doi:10.1016/S0140-6736(17)30933-9
   PubMed Web of Science ®Google Scholar
• Frantz C, Avouac J, Distler O, et al. Impaired quality of life in systemic sclerosis and patient perception of the disease: a large international survey. Semin Arthritis Rheum. 2016;46(1):115–123. doi:10.1016/j.semarthrit.2016.02.005
   PubMed Web of Science ®Google Scholar
• D’Oria M, Gandin I, Riccardo P, et al. Correlation between Microvascular Damage and Internal Organ Involvement in Scleroderma: focus on Lung Damage and Endothelial Dysfunction. Diagnostics. 2022;13(1):55. doi:10.3390/diagnostics13010055
   Web of Science ®Google Scholar
• van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum. 2013;65(11):2737–2747. doi:10.1002/art.38098
   PubMed Web of Science ®Google Scholar
• Nihtyanova SI, Schreiber BE, Ong VH, et al. Prediction of pulmonary complications and long-term survival in systemic sclerosis. Arthritis Rheumatol. 2014;66(6):1625–1635. doi:10.1002/art.38390
   PubMed Web of Science ®Google Scholar
• Khanna D, Lescoat A, Roofeh D, et al. Systemic Sclerosis-Associated Interstitial Lung Disease: how to Incorporate Two Food and Drug Administration-Approved Therapies in Clinical Practice. Arthritis Rheumatol. 2022;74(1):13–27. doi:10.1002/art.41933
   PubMed Web of Science ®Google Scholar
• Cavazzana I, Vojinovic T, Airo’ P, et al. Systemic Sclerosis-Specific Antibodies: novel and Classical Biomarkers. Clin Rev Allergy Immunol. 2022;64(3):412–430. doi:10.1007/s12016-022-08946-w
   PubMed Web of Science ®Google Scholar
• Soulaidopoulos S, Triantafyllidou E, Garyfallos A, et al. The role of nailfold capillaroscopy in the assessment of internal organ involvement in systemic sclerosis: a critical review. Autoimmun Rev. 2017;16(8):787–795. doi:10.1016/j.autrev.2017.05.019
   PubMed Web of Science ®Google Scholar
• Vondenberg JA, Muruganandam M, Nunez SE, Emil NS, Sibbitt WL. Increased malignancies in systemic sclerosis. Int J Rheum Dis. 2022;25(1):90–92. doi:10.1111/1756-185X.14244
   PubMed Web of Science ®Google Scholar
• Varjú C, Pauling JD, Saketkoo LA. Multi-Organ System Screening, Care, and Patient Support in Systemic Sclerosis. Rheum Dis Clin North Am. 2023;49(2):211–248. doi:10.1016/j.rdc.2023.01.002
   PubMed Web of Science ®Google Scholar
• Affandi AJ, Radstake TR, Marut W. Update on biomarkers in systemic sclerosis: tools for diagnosis and treatment. Semin Immunopathol. 2015;37(5):475–487. doi:10.1007/s00281-015-0506-4
   PubMed Web of Science ®Google Scholar
• Mihai C, Tervaert JW. Anti-endothelial cell antibodies in systemic sclerosis. Ann Rheum Dis. 2010;69(2):319–324. doi:10.1136/ard.2008.102400
   PubMed Web of Science ®Google Scholar
• Fineschi S, Goffin L, Rezzonico R, et al. Antifibroblast antibodies in systemic sclerosis induce fibroblasts to produce profibrotic chemokines, with partial exploitation of toll-like receptor 4. Arthritis Rheum. 2008;58(12):3913–3923. doi:10.1002/art.24049
   PubMedGoogle Scholar
• Moroncini G, Svegliati Baroni S, Gabrielli A. Agonistic antibodies in systemic sclerosis. Immunol Lett. 2018;195:83–87. doi:10.1016/j.imlet.2017.10.007
   PubMed Web of Science ®Google Scholar
• Sato S, Fujimoto M, Hasegawa M, et al. Serum soluble CTLA-4 levels are increased in diffuse cutaneous systemic sclerosis. Rheumatology. 2004;43(10):1261–1266. doi:10.1093/rheumatology/keh303
   PubMed Web of Science ®Google Scholar
• Tan FK, Arnett FC, Antohi S, et al. Autoantibodies to the extracellular matrix microfibrillar protein, fibrillin-1, in patients with scleroderma and other connective tissue diseases. J Immunol. 1999;163(2):1066–1072. doi:10.4049/jimmunol.163.2.1066
   PubMed Web of Science ®Google Scholar
• Fritzler MJ, Bentow C, Beretta L, et al. Anti-U11/U12 Antibodies as a Rare but Important Biomarker in Patients with Systemic Sclerosis: a Narrative Review. Diagnostics. 2023;13(7):1257. doi:10.3390/diagnostics13071257
   Web of Science ®Google Scholar
• Nihtyanova SI, Denton CP. Autoantibodies as predictive tools in systemic sclerosis. Nat Rev Rheumatol. 2010;6(2):112–116. doi:10.1038/nrrheum.2009.238
   PubMed Web of Science ®Google Scholar
• Clark KEN, Campochiaro C, Host LV, et al. Combinations of scleroderma hallmark autoantibodies associate with distinct clinical phenotypes. Sci Rep. 2022;12(1):11212. doi:10.1038/s41598-022-15062-4
   PubMed Web of Science ®Google Scholar
• Chepy A, Bourel L, Koether V, Launay D, Dubucquoi S, Sobanski V. Can Antinuclear Antibodies Have a Pathogenic Role in Systemic Sclerosis? Front Immunol. 2022;13:930970. doi:10.3389/fimmu.2022.930970
   PubMed Web of Science ®Google Scholar
• Tsai CY, Hsieh SC, Wu TH, et al. Pathogenic Roles of Autoantibodies and Aberrant Epigenetic Regulation of Immune and Connective Tissue Cells in the Tissue Fibrosis of Patients with Systemic Sclerosis. Int J Mol Sci. 2020;21(9):3069. doi:10.3390/ijms21093069
   PubMed Web of Science ®Google Scholar
• Hoa S, Lazizi S, Baron M, Wang M, Fritzler MJ, Hudson M; Canadian Scleroderma Research Group. Association between autoantibodies in systemic sclerosis and cancer in a national registry. Rheumatology. 2022;61(7):2905–2914. doi:10.1093/rheumatology/keab735
   PubMed Web of Science ®Google Scholar
• Liem SIE, Neppelenbroek S, Fehres CM, et al. Autoreactive B cell responses targeting nuclear antigens in systemic sclerosis: implications for disease pathogenesis. Semin Arthritis Rheum. 2023;58:152136. doi:10.1016/j.semarthrit.2022.152136
   PubMed Web of Science ®Google Scholar
• Loisel S, Lansiaux P, Rossille D, et al. Regulatory B Cells Contribute to the Clinical Response After Bone Marrow-Derived Mesenchymal Stromal Cell Infusion in Patients With Systemic Sclerosis. Stem Cells Transl Med. 2023:szad010. doi:10.1093/stcltm/szad010
   Web of Science ®Google Scholar
• Arnett FC. HLA and autoimmunity in scleroderma (systemic sclerosis). Int Rev Immunol. 1995;12(2–4):107–128. doi:10.3109/08830189509056707
   PubMedGoogle Scholar
• Kuwana M, Okano Y, Kaburaki J, Medsger TA, Wright TM. Autoantibodies to RNA polymerases recognize multiple subunits and demonstrate cross-reactivity with RNA polymerase complexes. Arthritis Rheum. 1999;42(2):275–284. doi:10.1002/1529-0131(199902)42:2<275::AID-ANR9>3.0.CO;2-P
   PubMedGoogle Scholar
• Kuwana M, Pandey JP, Silver RM, et al. HLA class II alleles in systemic sclerosis patients with anti-RNA polymerase I/III antibody: associations with subunit reactivities. J Rheumatol. 2003;30(11):2392–2397.
   PubMed Web of Science ®Google Scholar
• Hanson AL, Sahhar J, Ngian GS, et al. Contribution of HLA and KIR Alleles to Systemic Sclerosis Susceptibility and Immunological and Clinical Disease Subtypes. Front Genet. 2022;13:913196. doi:10.3389/fgene.2022.913196
   PubMed Web of Science ®Google Scholar
• Acosta-Herrera M, Kerick M, Lopéz-Isac E, et al. Comprehensive analysis of the major histocompatibility complex in systemic sclerosis identifies differential HLA associations by clinical and serological subtypes. Ann Rheum Dis. 2021;80(8):1040–1047. doi:10.1136/annrheumdis-2021-219884
   PubMed Web of Science ®Google Scholar
• Caselli E, Soffritti I, D’Accolti M, et al. HHV-6A Infection and Systemic Sclerosis: clues of a Possible Association. Microorganisms. 2019;8(1):39. doi:10.3390/microorganisms8010039
   PubMed Web of Science ®Google Scholar
• Gourh P, Safran SA, Alexander T, et al. HLA and autoantibodies define scleroderma subtypes and risk in African and European Americans and suggest a role for molecular mimicry. Proc Natl Acad Sci U S A. 2020;117(1):552–562. doi:10.1073/pnas.1906593116
   PubMed Web of Science ®Google Scholar
• Kerick M, Acosta-Herrera M, Simeón-Aznar CP, et al. Complement component C4 structural variation and quantitative traits contribute to sex-biased vulnerability in systemic sclerosis. NPJ Genom Med. 2022;7(1):57. doi:10.1038/s41525-022-00327-8
   PubMed Web of Science ®Google Scholar
• O’Reilly S. Toll-like receptor triggering in systemic sclerosis: time to target. Rheumatology. 2023;62(SI):SI12–SI19. doi:10.1093/rheumatology/keac421
   PubMedGoogle Scholar
• Bale S, Verma P, Varga J, Bhattacharyya S. Extracellular Matrix-Derived Damage-Associated Molecular Patterns: implications in Systemic Sclerosis and Fibrosis. J Invest Dermatol. 2023;143(10):1877–1885. doi:10.1016/j.jid.2023.04.030
   PubMedGoogle Scholar
• Choreño-Parra JA, Cervantes-Rosete D, Jiménez-álvarez LA, et al. Dendritic cells drive profibrotic inflammation and aberrant T cell polarization in systemic sclerosis. Rheumatology. 2023;62(4):1687–1698. doi:10.1093/rheumatology/keac489
   PubMed Web of Science ®Google Scholar
• Liu X, Mayes MD, Tan FK, et al. Correlation of interferon-inducible chemokine plasma levels with disease severity in systemic sclerosis. Arthritis Rheum. 2013;65(1):226–235. doi:10.1002/art.37742
   PubMed Web of Science ®Google Scholar
• Wang W, Bhattacharyya S, Marangoni RG, et al. The JAK/STAT pathway is activated in systemic sclerosis and is effectively targeted by tofacitinib. J Scleroderma Relat Disord. 2020;5(1):40–50. doi:10.1177/2397198319865367
   PubMed Web of Science ®Google Scholar
• Jiang S, Yang H, Li M. Emerging Roles of Lysophosphatidic Acid in Macrophages and Inflammatory Diseases. Int J Mol Sci. 2023;24(15):12524. doi:10.3390/ijms241512524
   PubMed Web of Science ®Google Scholar
• Akter T, Silver RM, Bogatkevich GS. Recent advances in understanding the pathogenesis of scleroderma-interstitial lung disease. Curr Rheumatol Rep. 2014;16(4):411. doi:10.1007/s11926-014-0411-1
   PubMed Web of Science ®Google Scholar
• Christmann RB, Sampaio-Barros P, Stifano G, et al. Association of Interferon- and transforming growth factor β-regulated genes and macrophage activation with systemic sclerosis-related progressive lung fibrosis. Arthritis Rheumatol. 2014;66(3):714–725. doi:10.1002/art.38288
   PubMed Web of Science ®Google Scholar
• Bellocchi C, Assassi S, Lyons M, et al. Proteomic aptamer analysis reveals serum markers that characterize preclinical systemic sclerosis (SSc) patients at risk for progression toward definite SSc. Arthritis Res Ther. 2023;25(1):15. doi:10.1186/s13075-023-02989-w
   PubMed Web of Science ®Google Scholar
• Kudo A, Kii I. Periostin function in communication with extracellular matrices. J Cell Commun Signal. 2018;12(1):301–308. doi:10.1007/s12079-017-0422-6
   PubMed Web of Science ®Google Scholar
• Kii I. Periostin Functions as a Scaffold for Assembly of Extracellular Proteins. Adv Exp Med Biol. 2019;1132:23–32.
   PubMed Web of Science ®Google Scholar
• El-Adili F, Lui JK, Najem M, et al. Periostin overexpression in scleroderma cardiac tissue and its utility as a marker for disease complications. Arthritis Res Ther. 2022;24(1):251. doi:10.1186/s13075-022-02943-2
   PubMed Web of Science ®Google Scholar
• Distler O, Distler J, Kowal-Bielecka O, Gay RE, Müller-Ladner U, Gay S. Chemokines and chemokine receptors in the pathogenesis of systemic sclerosis. Mod Rheumatol. 2002;12(2):107–112. doi:10.3109/s101650200019
   PubMedGoogle Scholar
• Bayati P, Poormoghim H, Mojtabavi N. Aberrant expression of miR-138 as a novel diagnostic biomarker in systemic sclerosis. Biomark Insights. 2022;17:11772719221135442. doi:10.1177/11772719221135442
   Web of Science ®Google Scholar
• Bayati P, Kalantari M, Assarehzadegan MA, Poormoghim H, Mojtabavi N. MiR-27a as a diagnostic biomarker and potential therapeutic target in systemic sclerosis. Sci Rep. 2022;12(1):18932. doi:10.1038/s41598-022-23723-7
   PubMed Web of Science ®Google Scholar
• Wajda A, Walczyk M, Dudek E, et al. Serum microRNAs in Systemic Sclerosis, Associations with Digital Vasculopathy and Lung Involvement. Int J Mol Sci. 2022;23(18):10731. doi:10.3390/ijms231810731
   PubMed Web of Science ®Google Scholar
• Iannazzo F, Pellicano C, Colalillo A, et al. Interleukin-33 and soluble suppression of tumorigenicity 2 in scleroderma cardiac involvement. Clin Exp Med. 2022;23(3):897–903. doi:10.1007/s10238-022-00864-7
   PubMed Web of Science ®Google Scholar
• Colalillo A, Pellicano C, Rosato E. Serum-soluble ST2 and systemic sclerosis arthropathy. Clin Rheumatol. 2023;42(3):871–877. doi:10.1007/s10067-022-06367-w
   PubMed Web of Science ®Google Scholar
• Michalska-Jakubus M, Cutolo M, Smith V, Krasowska D. Imbalanced serum levels of Ang1, Ang2 and VEGF in systemic sclerosis: integrated effects on microvascular reactivity. Microvasc Res. 2019;125:103881. doi:10.1016/j.mvr.2019.103881
   PubMed Web of Science ®Google Scholar
• Kakkar V, Assassi S, Allanore Y, et al. Type 1 interferon activation in systemic sclerosis: a biomarker, a target or the culprit. Curr Opin Rheumatol. 2022;34(6):357–364. doi:10.1097/BOR.0000000000000907
   PubMed Web of Science ®Google Scholar
• Ciechomska M, Skalska U. Targeting interferons as a strategy for systemic sclerosis treatment. Immunol Lett. 2018;195:45–54. doi:10.1016/j.imlet.2017.10.011
   PubMed Web of Science ®Google Scholar
• Londe AC, Fernandez-Ruiz R, Rogério Julio P, Appenzeller S, Niewold TB. Type I Interferons in Autoimmunity: implications in Clinical Phenotypes and Treatment Response. J Rheumatol. 2023;jrheum.2022–0827.
   Google Scholar
• Assassi S, Mayes MD, Arnett FC, et al. Systemic sclerosis and lupus: points in an interferon-mediated continuum. Arthritis Rheum. 2010;62(2):589–598. doi:10.1002/art.27224
   PubMed Web of Science ®Google Scholar
• Chaudhary V, Ah Kioon MD, Hwang SM, et al. Chronic activation of pDCs in autoimmunity is linked to dysregulated ER stress and metabolic responses. J Exp Med. 2022;219(11):e20221085. doi:10.1084/jem.20221085
   PubMed Web of Science ®Google Scholar
• Höppner J, Casteleyn V, Biesen R, et al. SIGLEC-1 in Systemic Sclerosis: a Useful Biomarker for Differential Diagnosis. Pharmaceuticals. 2022;15(10):1198. doi:10.3390/ph15101198
   Web of Science ®Google Scholar
• Wu M, Assassi S. Dysregulation of Type 1 Interferon Signaling in Systemic Sclerosis: a Promising Therapeutic Target? Curr Treatm Opt Rheumatol. 2021;7(4):349–360. doi:10.1007/s40674-021-00188-9
   PubMedGoogle Scholar
• Guo X, Higgs BW, Bay-Jensen AC, et al. Suppression of T cell activation and collagen accumulation by an anti-IFNAR1 mAb, anifrolumab, in adult patients with systemic sclerosis. J Invest Dermatol. 2015;135(10):2402–2409. doi:10.1038/jid.2015.188
   PubMed Web of Science ®Google Scholar
• Mendoza FA, Piera-Velazquez S, Jimenez SA. Tyrosine kinases in the pathogenesis of tissue fibrosis in systemic sclerosis and potential therapeutic role of their inhibition. Transl Res. 2021;231:139–158. doi:10.1016/j.trsl.2021.01.001
   PubMed Web of Science ®Google Scholar
• Wollin L, Maillet I, Quesniaux V, et al. Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis. J Pharmacol Exp Ther. 2014;349(2):209–220. doi:10.1124/jpet.113.208223
   PubMed Web of Science ®Google Scholar
• Wollin L, Wex E, Pautsch A, et al. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. Eur Respir J. 2015;45(5):1434–1445. doi:10.1183/09031936.00174914
   PubMed Web of Science ®Google Scholar
• Sato S, Shinohara S, Hayashi S, et al. Anti-fibrotic efficacy of nintedanib in pulmonary fibrosis via the inhibition of fibrocyte activity. Respir Res. 2017;18(1):172. doi:10.1186/s12931-017-0654-2
   PubMed Web of Science ®Google Scholar
• Avouac J, Fürnrohr BG, Tomcik M, et al. Inactivation of the transcription factor STAT-4 prevents inflammation-driven fibrosis in animal models of systemic sclerosis. Arthritis Rheum. 2011;63(3):800–809. doi:10.1002/art.30171
   PubMedGoogle Scholar
• Krishna Swaroop A, Krishnan Namboori PK, Esakkimuthukumar M, et al. Leveraging decagonal in-silico strategies for uncovering IL-6 inhibitors with precision. Comput Biol Med. 2023;163:107231. doi:10.1016/j.compbiomed.2023.107231
   PubMed Web of Science ®Google Scholar
• Sheng XR, Gao X, Schiffman C, et al. Biomarkers of fibrosis, inflammation, and extracellular matrix in the Phase 3 trial of tocilizumab in systemic sclerosis. Clin Immunol. 2023;254:109695. doi:10.1016/j.clim.2023.109695
   PubMed Web of Science ®Google Scholar
• Khanna D, Lin CJF, Furst DE, et al. Long-Term Safety and Efficacy of Tocilizumab in Early Systemic Sclerosis-Interstitial Lung Disease: open-Label Extension of a Phase 3 Randomized Controlled Trial. Am J Respir Crit Care Med. 2022;205(6):674–684. doi:10.1164/rccm.202103-0714OC
   PubMed Web of Science ®Google Scholar
• Junfei Z, Meihua G, Shuai Z, et al. Retrospective comparative study of the efficacy of JAK inhibitor (tofacitinib) in the treatment of systemic sclerosis-associated interstitial lung disease. Clin Rheumatol. 2023;42(10):2823–2832. doi:10.1007/s10067-023-06660-2
   PubMed Web of Science ®Google Scholar
• Moriana C, Moulinet T, Jaussaud R, Decker P. JAK inhibitors and systemic sclerosis: a systematic review of the literature. Autoimmun Rev. 2022;21(10):103168. doi:10.1016/j.autrev.2022.103168
   PubMed Web of Science ®Google Scholar
• Kuszmiersz P, Pacholczak-Madej R, Siwiec A, et al. Thrombin generation potential is enhanced in systemic sclerosis: impact of selected endothelial biomarkers. Clin Exp Rheumatol. 2021;39 Suppl 131(4):13–19. doi:10.55563/clinexprheumatol/d03dnc
   PubMed Web of Science ®Google Scholar
• Colic J, Pruner I, Damjanov N, et al. Impaired Fibrinolysis Is Linked With Digital Vasculopathy and Onset of New Digital Ulcers in Systemic Sclerosis. J Rheumatol. 2022;49(6):598–606. doi:10.3899/jrheum.210931
   PubMed Web of Science ®Google Scholar
• Silver RM, Wilson DA, Akter T, et al. Safety and Tolerability of Thrombin Inhibition in Scleroderma-Associated Interstitial Lung Disease. ACR Open Rheumatol. 2019;1(7):403–411. doi:10.1002/acr2.11049
   PubMedGoogle Scholar
• Liu Y, Wang J, Luo S, Zhan Y, Lu Q. The roles of PPARγ and its agonists in autoimmune diseases: a comprehensive review. J Autoimmun. 2020;113:102510. doi:10.1016/j.jaut.2020.102510
   PubMed Web of Science ®Google Scholar
• Leask A. Possible strategies for anti-fibrotic drug intervention in scleroderma. J Cell Commun Signal. 2011;5(2):125–129. doi:10.1007/s12079-011-0122-6
   PubMed Web of Science ®Google Scholar
• Ghosh AK, Bhattacharyya S, Wei J, et al. Peroxisome proliferator-activated receptor-gamma abrogates Smad-dependent collagen stimulation by targeting the p300 transcriptional coactivator. FASEB J. 2009;23(9):2968–2977. doi:10.1096/fj.08-128736
   PubMed Web of Science ®Google Scholar
• Wei J, Ghosh AK, Sargent JL, et al. PPARγ downregulation by TGFß in fibroblast and impaired expression and function in systemic sclerosis: a novel mechanism for progressive fibrogenesis. PLoS One. 2010;5(11):e13778. doi:10.1371/journal.pone.0013778
   PubMed Web of Science ®Google Scholar
• Lakota K, Wei J, Carns M, et al. Levels of adiponectin, a marker for PPAR-gamma activity, correlate with skin fibrosis in systemic sclerosis: potential utility as biomarker? Arthritis Res Ther. 2012;14(3):R102. doi:10.1186/ar3827
   PubMed Web of Science ®Google Scholar
• Żółkiewicz J, Stochmal A, Zaremba M, et al. Circulating peroxisome proliferator-activated receptor γ is elevated in systemic sclerosis. Postepy Dermatol Alergol. 2020;37(6):921–926. doi:10.5114/ada.2019.84746
   PubMed Web of Science ®Google Scholar
• Derrett-Smith E, Clark KEN, Shiwen X, et al. The pan-PPAR agonist lanifibranor reduces development of lung fibrosis and attenuates cardiorespiratory manifestations in a transgenic mouse model of systemic sclerosis. Arthritis Res Ther. 2021;23(1):234. doi:10.1186/s13075-021-02592-x
   PubMed Web of Science ®Google Scholar
• Tigyi G. Aiming drug discovery at lysophosphatidic acid targets. Br J Pharmacol. 2010;161(2):241–270. doi:10.1111/j.1476-5381.2010.00815.x
   PubMed Web of Science ®Google Scholar
• Tokumura A, Carbone LD, Yoshioka Y, et al. Elevated serum levels of arachidonoyl-lysophosphatidic acid and sphingosine 1-phosphate in systemic sclerosis. Int J Med Sci. 2009;6(4):168–176. doi:10.7150/ijms.6.168
   PubMed Web of Science ®Google Scholar
• Allanore Y, Distler O, Jagerschmidt A, et al. Lysophosphatidic Acid Receptor 1 Antagonist SAR100842 for Patients With Diffuse Cutaneous Systemic Sclerosis: a Double-Blind, Randomized, Eight-Week Placebo-Controlled Study Followed by a Sixteen-Week Open-Label Extension Study. Arthritis Rheumatol. 2018;70(10):1634–1643. doi:10.1002/art.40547
   PubMed Web of Science ®Google Scholar
• Feng D, Gerarduzzi C. Emerging Roles of Matricellular Proteins in Systemic Sclerosis. Int J Mol Sci. 2020;21(13):4776. doi:10.3390/ijms21134776
   PubMed Web of Science ®Google Scholar
• Leong E, Bezuhly M, Marshall JS. Distinct Metalloproteinase Expression and Functions in Systemic Sclerosis and Fibrosis: what We Know and the Potential for Intervention. Front Physiol. 2021;12:727451. doi:10.3389/fphys.2021.727451
   PubMed Web of Science ®Google Scholar
• Peng WJ, Yan JW, Wan YN, et al. Matrix metalloproteinases: a review of their structure and role in systemic sclerosis. J Clin Immunol. 2012;32(6):1409–1414. doi:10.1007/s10875-012-9735-7
   PubMed Web of Science ®Google Scholar
• Elias GJ, Ioannis M, Theodora P, et al. Circulating tissue inhibitor of matrix metalloproteinase-4 (TIMP-4) in systemic sclerosis patients with elevated pulmonary arterial pressure. Mediators Inflamm. 2008;2008:164134. doi:10.1155/2008/164134
   PubMed Web of Science ®Google Scholar
• Mazzotta C, Romano E, Bruni C, et al. Plexin-D1/Semaphorin 3E pathway may contribute to dysregulation of vascular tone control and defective angiogenesis in systemic sclerosis. Arthritis Res Ther. 2015;17(1):221. doi:10.1186/s13075-015-0749-4
   PubMedGoogle Scholar
• Romano E, Rosa I, Fioretto BS, Matucci-Cerinic M, Manetti M. Circulating Neurovascular Guidance Molecules and Their Relationship with Peripheral Microvascular Impairment in Systemic Sclerosis. Life. 2022;12(7):1056. doi:10.3390/life12071056
   PubMedGoogle Scholar
• Nakamura K, Asano Y, Taniguchi T, et al. Serum levels of interleukin-18-binding protein isoform a: clinical association with inflammation and pulmonary hypertension in systemic sclerosis. J Dermatol. 2016;43(8):912–918. doi:10.1111/1346-8138.13252
   PubMed Web of Science ®Google Scholar
• Fioretto BS, Rosa I, Matucci-Cerinic M, Romano E, Manetti M. Current Trends in Vascular Biomarkers for Systemic Sclerosis: a Narrative Review. Int J Mol Sci. 2023;24(4):4097. doi:10.3390/ijms24044097
   PubMed Web of Science ®Google Scholar
• Kardum Ž, Milas-Ahić J, Šahinović I, Masle AM, Uršić D, Kos M. Serum levels of interleukin 17 and 22 in patients with systemic sclerosis: a single-center cross-sectional study. Rheumatol Int. 2023;43(2):345–354. doi:10.1007/s00296-022-05250-w
   PubMed Web of Science ®Google Scholar
• Robak E, Gerlicz-Kowalczuk Z, Dziankowska-Bartkowiak B, Wozniacka A, Bogaczewicz J. Serum concentrations of IL-17A, IL-17B, IL-17E and IL-17F in patients with systemic sclerosis. Arch Med Sci. 2019;15(3):706–712. doi:10.5114/aoms.2019.84738
   PubMed Web of Science ®Google Scholar
• Ikawa T, Miyagawa T, Fukui Y, et al. Association of serum CCL20 levels with pulmonary vascular involvement and primary biliary cholangitis in patients with systemic sclerosis. Int J Rheum Dis. 2021;24(5):711–718. doi:10.1111/1756-185X.14103
   PubMed Web of Science ®Google Scholar
• Didriksen H, Molberg Ø, Mehta A, et al. Target organ expression and biomarker characterization of chemokine CCL21 in systemic sclerosis associated pulmonary arterial hypertension. Front Immunol. 2022;13:991743. doi:10.3389/fimmu.2022.991743
   PubMed Web of Science ®Google Scholar
• Yanaba K, Yoshizaki A, Muroi E, et al. Serum CCL23 levels are increased in patients with systemic sclerosis. Arch Dermatol Res. 2011;303(1):29–34. doi:10.1007/s00403-010-1078-8
   PubMed Web of Science ®Google Scholar
• Cossu M, van Bon L, Preti C, Rossato M, Beretta L, Radstake TRDJ. Earliest Phase of Systemic Sclerosis Typified by Increased Levels of Inflammatory Proteins in the Serum. Arthritis Rheumatol. 2017;69(12):2359–2369. doi:10.1002/art.40243
   PubMed Web of Science ®Google Scholar
• Hasegawa M, Sato S, Echigo T, Hamaguchi Y, Yasui M, Takehara K. Up regulated expression of fractalkine/CX3CL1 and CX3CR1 in patients with systemic sclerosis. Ann Rheum Dis. 2005;64(1):21–28. doi:10.1136/ard.2003.018705
   PubMed Web of Science ®Google Scholar
• Taniguchi T, Asano Y, Akamata K, et al. Serum levels of galectin-3: possible association with fibrosis, aberrant angiogenesis, and immune activation in patients with systemic sclerosis. J Rheumatol. 2012;39(3):539–544. doi:10.3899/jrheum.110755
   PubMed Web of Science ®Google Scholar
• Pellicano C, Romaggioli L, Miglionico M, et al. Maresin1 is a predictive marker of new digital ulcers in systemic sclerosis patients. Microvasc Res. 2022;142:104366. doi:10.1016/j.mvr.2022.104366
   PubMed Web of Science ®Google Scholar
• Arakawa H, Jinnin M, Muchemwa FC, et al. Adiponectin expression is decreased in the involved skin and sera of diffuse cutaneous scleroderma patients. Exp Dermatol. 2011;20(9):764–766. doi:10.1111/j.1600-0625.2011.01310.x
   PubMed Web of Science ®Google Scholar
• Stratton RJ, Pompon L, Coghlan JG, et al. Soluble thrombomodulin concentration is raised in scleroderma associated pulmonary hypertension. Ann Rheum Dis. 2000;59(2):132–134. doi:10.1136/ard.59.2.132
   PubMed Web of Science ®Google Scholar
• Hassan WA, Baraka EA, Elnady BM, et al. Serum Soluble CD163 and its association with various disease parameters in patients with systemic sclerosis. Eur J Rheumatol. 2016;3(3):95–100. doi:10.5152/eurjrheum.2016.15088
   PubMed Web of Science ®Google Scholar
• Nowaczyk J, Blicharz L, Zawistowski M, et al. The Clinical Significance of Salusins in Systemic Sclerosis-A Cross-Sectional Study. Diagnostics. 2023;13(5):848. doi:10.3390/diagnostics13050848
   Web of Science ®Google Scholar
• Servaas NH, Hiddingh S, Chouri E, et al. Nuclear Receptor Subfamily 4A Signaling as a Key Disease Pathway of CD1c+ Dendritic Cell Dysregulation in Systemic Sclerosis. Arthritis Rheumatol. 2023;75(2):279–292. doi:10.1002/art.42319
   PubMed Web of Science ®Google Scholar
• Morales-González V, Galeano-Sánchez D, Covaleda-Vargas JE, et al. Metabolic fingerprinting of systemic sclerosis: a systematic review. Front Mol Biosci. 2023;10:1215039. doi:10.3389/fmolb.2023.1215039
   PubMed Web of Science ®Google Scholar
• Perelas A, Silver RM, Arrossi AV, Highland KB. Systemic sclerosis-associated interstitial lung disease. Lancet Respir Med. 2020;8(3):304–320. doi:10.1016/S2213-2600(19)30480-1
   PubMed Web of Science ®Google Scholar
• Hoffmann-Vold AM, Allanore Y, Alves M, et al. Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database. Ann Rheum Dis. 2021;80(2):219–227. doi:10.1136/annrheumdis-2020-217455
   PubMed Web of Science ®Google Scholar
• Tyndall AJ, Bannert B, Vonk M, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis. 2010;69(10):1809–1815. doi:10.1136/ard.2009.114264
   PubMed Web of Science ®Google Scholar
• Steen V. Predictors of end stage lung disease in systemic sclerosis. Ann Rheum Dis. 2003;62(2):97–99. doi:10.1136/ard.62.2.97
   PubMed Web of Science ®Google Scholar
• Wangkaew S, Euathrongchit J, Wattanawittawas P, Kasitanon N, Louthrenoo W. Incidence and predictors of interstitial lung disease (ILD) in Thai patients with early systemic sclerosis: inception cohort study. Mod Rheumatol. 2016;26(4):588–593. doi:10.3109/14397595.2015.1115455
   PubMed Web of Science ®Google Scholar
• Giacomelli R, Liakouli V, Berardicurti O, et al. Interstitial lung disease in systemic sclerosis: current and future treatment. Rheumatol Int. 2017;37(6):853–863. doi:10.1007/s00296-016-3636-7
   PubMed Web of Science ®Google Scholar
• Wells AU, Denton CP. Interstitial lung disease in connective tissue disease--mechanisms and management. Nat Rev Rheumatol. 2014;10(12):728–739. doi:10.1038/nrrheum.2014.149
   PubMed Web of Science ®Google Scholar
• Ahmed S, Handa R. Management of Connective Tissue Disease-related Interstitial Lung Disease. Curr Pulmonol Rep. 2022;11(3):86–98. doi:10.1007/s13665-022-00290-w
   PubMed Web of Science ®Google Scholar
• DeMizio DJ, Bernstein EJ. Detection and classification of systemic sclerosis-related interstitial lung disease: a review. Curr Opin Rheumatol. 2019;31(6):553–560. doi:10.1097/BOR.0000000000000660
   PubMed Web of Science ®Google Scholar
• Distler O, Assassi S, Cottin V, et al. Predictors of progression in systemic sclerosis patients with interstitial lung disease. Eur Respir J. 2020;55(5):1902026. doi:10.1183/13993003.02026-2019
   PubMed Web of Science ®Google Scholar
• Temiz Karadag D, Cakir O, San S, Yazici A, Ciftci E, Cefle A. Association of quantitative computed tomography indices with lung function and extent of pulmonary fibrosis in patients with systemic sclerosis. Clin Rheumatol. 2022;41(2):513–521. doi:10.1007/s10067-021-05918-x
   PubMed Web of Science ®Google Scholar
• Gasperini ML, Gigante A, Iacolare A, Pellicano C, Lucci S, Rosato E. The predictive role of lung ultrasound in progression of scleroderma interstitial lung disease. Clin Rheumatol. 2020;39(1):119–123. doi:10.1007/s10067-019-04686-z
   PubMed Web of Science ®Google Scholar
• Khanna D, Mittoo S, Aggarwal R, et al. Connective Tissue Disease-associated Interstitial Lung Diseases (CTD-ILD) - Report from OMERACT CTD-ILD Working Group. J Rheumatol. 2015;42(11):2168–2171. doi:10.3899/jrheum.141182
   PubMed Web of Science ®Google Scholar
• Kowal-Bielecka O, Fransen J, Avouac J, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017;76(8):1327–1339. doi:10.1136/annrheumdis-2016-209909
   PubMed Web of Science ®Google Scholar
• Denton CP, De Lorenzis E, Roblin E, et al. Management of systemic sclerosis: British Society for Rheumatology guideline scope. Rheumatol Adv Pract. 2023;7(1):rkad022. doi:10.1093/rap/rkad022
   PubMedGoogle Scholar
• Raghu G, MontesiSB, Silver RM, et al. Treatment of Systemic Sclerosis-associated Interstitial Lung Disease: Evidence-based Recommendations. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med. In press 2023. doi:10.1164/rccm.202306-1113ST
   Google Scholar
• de Vries-Bouwstra JK, Allanore Y, Matucci-Cerinic M, Balbir-Gurman A. Worldwide Expert Agreement on Updated Recommendations for the Treatment of Systemic Sclerosis. J Rheumatol. 2020;47(2):249–254. doi:10.3899/jrheum.181173
   PubMed Web of Science ®Google Scholar
• Hoffmann-Vold AM, Maher TM, Philpot EE, Ashrafzadeh A, Distler O. Assessment of recent evidence for the management of patients with systemic sclerosis-associated interstitial lung disease: a systematic review. ERJ Open Res. 2021;7(1):00235–2020. doi:10.1183/23120541.00235-2020
   PubMedGoogle Scholar
• Furue M, Mitoma C, Mitoma H, et al. Pathogenesis of systemic sclerosis-current concept and emerging treatments. Immunol Res. 2017;65(4):790–797. doi:10.1007/s12026-017-8926-y
   PubMed Web of Science ®Google Scholar
• Petrova DT, Brandhorst G, Koch C, et al. Mycophenolic acid reverses TGF beta-induced cell motility, collagen matrix contraction and cell morphology in vitro. Cell Biochem Funct. 2015;33(7):503–508. doi:10.1002/cbf.3149
   PubMed Web of Science ®Google Scholar
• Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology. 2000;47(2–3):85–118. doi:10.1016/S0162-3109(00)00188-0
   PubMed Web of Science ®Google Scholar
• Denton CP, Ong VH, Xu S, et al. Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis. Ann Rheum Dis. 2018;77(9):1362–1371. doi:10.1136/annrheumdis-2018-213031
   PubMed Web of Science ®Google Scholar
• Khanna D, Padilla C, Tsoi LC, et al. Tofacitinib blocks IFN-regulated biomarker genes in skin fibroblasts and keratinocytes in a systemic sclerosis trial. JCI Insight. 2022;7(17):e159566. doi:10.1172/jci.insight.159566
   PubMed Web of Science ®Google Scholar
• Numajiri H, Kuzumi A, Fukasawa T, et al. B Cell Depletion Inhibits Fibrosis via Suppression of Profibrotic Macrophage Differentiation in a Mouse Model of Systemic Sclerosis. Arthritis Rheumatol. 2021;73(11):2086–2095. doi:10.1002/art.41798
   PubMed Web of Science ®Google Scholar
• Acharya N, Sharma SK, Mishra D, Dhooria S, Dhir V, Jain S. Efficacy and safety of pirfenidone in systemic sclerosis-related interstitial lung disease-a randomised controlled trial. Rheumatol Int. 2020;40(5):703–710. doi:10.1007/s00296-020-04565-w
   PubMed Web of Science ®Google Scholar
• Sullivan KM, Goldmuntz EA, Keyes-Elstein L, et al. Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma. N Engl J Med. 2018;378(1):35–47. doi:10.1056/NEJMoa1703327
   PubMed Web of Science ®Google Scholar
• Bernstein EJ, Peterson ER, Sell JL, et al. Survival of adults with systemic sclerosis following lung transplantation: a nationwide cohort study. Arthritis Rheumatol. 2015;67(5):1314–1322. doi:10.1002/art.39021
   PubMed Web of Science ®Google Scholar
• Nihtyanova SI, Sari A, Harvey JC, et al. Using Autoantibodies and Cutaneous Subset to Develop Outcome-Based Disease Classification in Systemic Sclerosis. Arthritis Rheumatol. 2020;72(3):465–476. doi:10.1002/art.41153
   PubMed Web of Science ®Google Scholar
• Kuwana M, Gil-Vila A, Selva-O’Callaghan A. Role of autoantibodies in the diagnosis and prognosis of interstitial lung disease in autoimmune rheumatic disorders. Ther Adv Musculoskelet Dis. 2021;13:1759720X211032457. doi:10.1177/1759720X211032457
   PubMed Web of Science ®Google Scholar
• Geroldinger-Simić M, Bayati S, Pohjanen E, Sepp N, Nilsson P, Pin E. Autoantibodies against PIP4K2B and AKT3 Are Associated with Skin and Lung Fibrosis in Patients with Systemic Sclerosis. Int J Mol Sci. 2023;24(6):5629. doi:10.3390/ijms24065629
   PubMed Web of Science ®Google Scholar
• Jog NR, James JA. Biomarkers in connective tissue diseases. J Allergy Clin Immunol. 2017;140(6):1473–1483. doi:10.1016/j.jaci.2017.10.003
   PubMed Web of Science ®Google Scholar
• Stock CJW, Renzoni EA. Genetic predictors of systemic sclerosis-associated interstitial lung disease: a review of recent literature. Eur J Hum Genet. 2018;26(6):765–777. doi:10.1038/s41431-018-0104-8
   PubMed Web of Science ®Google Scholar
• Elhai M, Avouac J, Allanore Y. Circulating lung biomarkers in idiopathic lung fibrosis and interstitial lung diseases associated with connective tissue diseases: where do we stand? Semin Arthritis Rheum. 2020;50(3):480–491. doi:10.1016/j.semarthrit.2020.01.006
   PubMed Web of Science ®Google Scholar
• Fields A, Potel KN, Cabuhal R, Aziri B, Stewart ID, Schock BC. Mediators of systemic sclerosis-associated interstitial lung disease (SSc-ILD): systematic review and meta-analyses. Thorax. 2022:thoraxjnl-2022–219226. doi:10.1136/thorax-2022-219226
   Web of Science ®Google Scholar
• Bonhomme O, André B, Gester F, et al. Biomarkers in systemic sclerosis-associated interstitial lung disease: review of the literature. Rheumatology. 2019;58(9):1534–1546. doi:10.1093/rheumatology/kez230
   PubMed Web of Science ®Google Scholar
• Elhai M, Hoffmann-Vold AM, Avouac J, et al. Performance of Candidate Serum Biomarkers for Systemic Sclerosis-Associated Interstitial Lung Disease. Arthritis Rheumatol. 2019;71(6):972–982. doi:10.1002/art.40815
   PubMed Web of Science ®Google Scholar
• Jee AS, Sahhar J, Youssef P, et al. Review: serum biomarkers in idiopathic pulmonary fibrosis and systemic sclerosis associated interstitial lung disease - frontiers and horizons. Pharmacol Ther. 2019;202:40–52. doi:10.1016/j.pharmthera.2019.05.014
   PubMed Web of Science ®Google Scholar
• Pietraforte I, Butera A, Gaddini L, et al. CXCL4-RNA Complexes Circulate in Systemic Sclerosis and Amplify Inflammatory/Pro-Fibrotic Responses by Myeloid Dendritic Cells. Int J Mol Sci. 2022;24(1):653. doi:10.3390/ijms24010653
   PubMed Web of Science ®Google Scholar
• Hoffmann-Vold AM, Fretheim H, Meier C, Maurer B. Circulating biomarkers of systemic sclerosis - interstitial lung disease. J Scleroderma Relat Disord. 2020;5(2 Suppl):41–47. doi:10.1177/2397198319894851
   PubMed Web of Science ®Google Scholar
• Mauer J, Chaurasia B, Goldau J, et al. Signaling by IL-6 promotes alternative activation of macrophages to limit endotoxemia and obesity-associated resistance to insulin. Nat Immunol. 2014;15(5):423–430. doi:10.1038/ni.2865
   PubMed Web of Science ®Google Scholar
• Sanges S, Guerrier T, Duhamel A, et al. Soluble markers of B cell activation suggest a role of B cells in the pathogenesis of systemic sclerosis-associated pulmonary arterial hypertension. Front Immunol. 2022;13:954007. doi:10.3389/fimmu.2022.954007
   PubMed Web of Science ®Google Scholar
• Ho KT, Reveille JD. The clinical relevance of autoantibodies in scleroderma. Arthritis Res Ther. 2003;5(2):80–93. doi:10.1186/ar628
   PubMed Web of Science ®Google Scholar
• Manetti M, Rosa I, Fioretto BS, Matucci-Cerinic M, Romano E. Decreased Serum Levels of SIRT1 and SIRT3 Correlate with Severity of Skin and Lung Fibrosis and Peripheral Microvasculopathy in Systemic Sclerosis. J Clin Med. 2022;11(5):1362. doi:10.3390/jcm11051362
   PubMed Web of Science ®Google Scholar
• Wu M, Baron M, Pedroza C, et al. CCL2 in the Circulation Predicts Long-Term Progression of Interstitial Lung Disease in Patients With Early Systemic Sclerosis: data From Two Independent Cohorts. Arthritis Rheumatol. 2017;69(9):1871–1878. doi:10.1002/art.40171
   PubMed Web of Science ®Google Scholar
• Omori I, Sumida H, Sugimori A, et al. Serum cold-inducible RNA-binding protein levels as a potential biomarker for systemic sclerosis-associated interstitial lung disease. Sci Rep. 2023;13(1):5017. doi:10.1038/s41598-023-32231-1
   PubMed Web of Science ®Google Scholar
• Jee AS, Stewart I, Youssef P, et al. A composite serum biomarker index for the diagnosis of systemic sclerosis interstitial lung disease: a multicentre, observational, cohort study. Arthritis Rheumatol. 2023;75(8):1424–1433. doi:10.1002/art.42491
   PubMed Web of Science ®Google Scholar
• Bauer Y, de Bernard S, Hickey P, et al. Identifying early pulmonary arterial hypertension biomarkers in systemic sclerosis: machine learning on proteomics from the DETECT cohort. Eur Respir J. 2021;57(6):2002591. doi:10.1183/13993003.02591-2020
   PubMed Web of Science ®Google Scholar
• Huang H, Fava A, Guhr T, et al. A methodology for exploring biomarker--phenotype associations: application to flow cytometry data and systemic sclerosis clinical manifestations. BMC Bioinform. 2015;16:293. doi:10.1186/s12859-015-0722-x
   PubMed Web of Science ®Google Scholar
• Yu L, Domsic RT, Saketkoo LA, et al. Assessment of the Systemic Sclerosis-Associated Raynaud’s Phenomenon Questionnaire: item Bank and Short-Form Development. Arthritis Care Res. 2022. doi:10.1002/acr.25038
   Web of Science ®Google Scholar
• Asano Y. The Pathogenesis of Systemic Sclerosis: an Understanding Based on a Common Pathologic Cascade across Multiple Organs and Additional Organ-Specific Pathologies. J Clin Med. 2020;9(9):2687. doi:10.3390/jcm9092687
   PubMed Web of Science ®Google Scholar
• Sundaram SM, Chung L. An Update on Systemic Sclerosis-Associated Pulmonary Arterial Hypertension: a Review of the Current Literature. Curr Rheumatol Rep. 2018;20(2):10. doi:10.1007/s11926-018-0709-5
   PubMed Web of Science ®Google Scholar
• Theodorakopoulou MP, Minopoulou I, Sarafidis P, et al. Vascular endothelial injury assessed with functional techniques in systemic sclerosis patients with pulmonary arterial hypertension versus systemic sclerosis patients without pulmonary arterial hypertension: a systematic review and meta-analysis. Rheumatol Int. 2021;41(6):1045–1053. doi:10.1007/s00296-021-04850-2
   PubMed Web of Science ®Google Scholar
• Pattanaik D, Brown M, Postlethwaite AE. Vascular involvement in systemic sclerosis (scleroderma). J Inflamm Res. 2011;4:105–125. doi:10.2147/JIR.S18145
   PubMedGoogle Scholar
• Yaqub A, Chung L. Epidemiology and risk factors for pulmonary hypertension in systemic sclerosis. Curr Rheumatol Rep. 2013;15(1):302. doi:10.1007/s11926-012-0302-2
   PubMed Web of Science ®Google Scholar
• Huang WC, Hsieh SC, Wu YW, et al. 2023 Taiwan Society of Cardiology (TSOC) and Taiwan College of Rheumatology (TCR) Joint Consensus on Connective Tissue Disease-Associated Pulmonary Arterial Hypertension. Acta Cardiol Sin. 2023;39(2):213–241. doi:10.6515/ACS.202303_39(2).20230117A
   PubMed Web of Science ®Google Scholar
• Bruni C, De Luca G, Lazzaroni MG, et al. Screening for pulmonary arterial hypertension in systemic sclerosis: a systematic literature review. Eur J Intern Med. 2020;78:17–25. doi:10.1016/j.ejim.2020.05.042
   PubMed Web of Science ®Google Scholar
• Jiang Y, Turk MA, Pope JE. Factors associated with pulmonary arterial hypertension (PAH) in systemic sclerosis (SSc). Autoimmun Rev. 2020;19(9):102602. doi:10.1016/j.autrev.2020.102602
   PubMed Web of Science ®Google Scholar
• Lewis RA, Durrington C, Condliffe R, Kiely DG. BNP/NT-proBNP in pulmonary arterial hypertension: time for point-of-care testing? Eur Respir Rev. 2020;29(156):200009. doi:10.1183/16000617.0009-2020
   PubMed Web of Science ®Google Scholar
• Semalulu T, Rudski L, Huynh T, et al. An evidence-based strategy to screen for pulmonary arterial hypertension in systemic sclerosis. Semin Arthritis Rheum. 2020;50(6):1421–1427. doi:10.1016/j.semarthrit.2020.02.013
   PubMed Web of Science ®Google Scholar
• Giuggioli D, Bruni C, Cacciapaglia F, et al. Pulmonary arterial hypertension: guidelines and unmet clinical needs. Reumatismo. 2021;72(4):228–246. doi:10.4081/reumatismo.2020.1310
   PubMed Web of Science ®Google Scholar
• Piera-Velazquez S, Dillon ST, Gu X, Libermann TA, Jimenez SA, Nita-Lazar A. Aptamer proteomics of serum exosomes from patients with Primary Raynaud’s and patients with Raynaud’s at risk of evolving into Systemic Sclerosis. PLoS One. 2022;17(12):e0279461. doi:10.1371/journal.pone.0279461
   PubMed Web of Science ®Google Scholar
• Bernero E, Sulli A, Ferrari G, et al. Prospective capillaroscopy-based study on transition from primary to secondary Raynaud’s phenomenon: preliminary results. Reumatismo. 2013;65(4):186–191. doi:10.4081/reumatismo.2013.186
   PubMedGoogle Scholar
• Ruaro B, Smith V, Sulli A, et al. Innovations in the Assessment of Primary and Secondary Raynaud’s Phenomenon. Front Pharmacol. 2019;10:360. doi:10.3389/fphar.2019.00360
   PubMed Web of Science ®Google Scholar
• D’Alessandro R, Garcia Gonzalez E, et al. Peripheral Macrovascular Involvement in Systemic Sclerosis: a Cohort Study by Color and Spectral Doppler Ultrasonography. Life. 2023;13(2):487. doi:10.3390/life13020487
   PubMedGoogle Scholar
• Belch J, Carlizza A, Carpentier PH, et al. ESVM guidelines - The diagnosis and management of Raynaud’s phenomenon. Vasa. 2017;46(6):413–423. doi:10.1024/0301-1526/a000661
   PubMed Web of Science ®Google Scholar
• Hickey PM, Lawrie A, Condliffe R. Circulating Protein Biomarkers in Systemic Sclerosis Related Pulmonary Arterial Hypertension: a Review of Published Data. Front Med. 2018;5:175. doi:10.3389/fmed.2018.00175
   Web of Science ®Google Scholar
• Moccaldi B, De Michieli L, Binda M, et al. Serum Biomarkers in Connective Tissue Disease-Associated Pulmonary Arterial Hypertension. Int J Mol Sci. 2023;24(4):4178. doi:10.3390/ijms24044178
   PubMed Web of Science ®Google Scholar
• Matucci-Cerinic M, Kahaleh B, Wigley FM. Review: evidence that systemic sclerosis is a vascular disease. Arthritis Rheum. 2013;65(8):1953–1962. doi:10.1002/art.37988
   PubMed Web of Science ®Google Scholar
• Zanin-Silva DC, Santana-Gonçalves M, Kawashima-Vasconcelos MY, Oliveira MC. Management of Endothelial Dysfunction in Systemic Sclerosis: current and Developing Strategies. Front Med. 2021;8:788250. doi:10.3389/fmed.2021.788250
   PubMed Web of Science ®Google Scholar
• Pulito-Cueto V, Genre F, López-Mejías R, et al. Endothelin-1 as a Biomarker of Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Associated with Autoimmune Diseases. Int J Mol Sci. 2023;24(2):1275. doi:10.3390/ijms24021275
   PubMed Web of Science ®Google Scholar
• Manetti M, Romano E, Rosa I, et al. Endothelial-to-mesenchymal transition contributes to endothelial dysfunction and dermal fibrosis in systemic sclerosis. Ann Rheum Dis. 2017;76(5):924–934. doi:10.1136/annrheumdis-2016-210229
   PubMed Web of Science ®Google Scholar
• Manetti M, Guiducci S, Romano E, et al. Differential expression of junctional adhesion molecules in different stages of systemic sclerosis. Arthritis Rheum. 2013;65(1):247–257. doi:10.1002/art.37712
   PubMedGoogle Scholar
• Moschetti L, Piantoni S, Vizzardi E, et al. Endothelial Dysfunction in Systemic Lupus Erythematosus and Systemic Sclerosis: a Common Trigger for Different Microvascular Diseases. Front Med. 2022;9:849086. doi:10.3389/fmed.2022.849086
   Web of Science ®Google Scholar
• Chora I, Guiducci S, Manetti M, et al. Vascular biomarkers and correlation with peripheral vasculopathy in systemic sclerosis. Autoimmun Rev. 2015;14(4):314–322. doi:10.1016/j.autrev.2014.12.001
   PubMed Web of Science ®Google Scholar
• Sha W, Thompson K, South J, et al. Loss of PPARγ expression by fibroblasts enhances dermal wound closure. Fibrogenesis Tissue Repair. 2012;5(1):5. doi:10.1186/1755-1536-5-5
   PubMedGoogle Scholar
• Avouac J, Meune C, Ruiz B, et al. Angiogenic biomarkers predict the occurrence of digital ulcers in systemic sclerosis. Ann Rheum Dis. 2012;71(3):394–399. doi:10.1136/annrheumdis-2011-200143
   PubMed Web of Science ®Google Scholar
• Iannone F, Riccardi MT, Guiducci S, et al. Bosentan regulates the expression of adhesion molecules on circulating T cells and serum soluble adhesion molecules in systemic sclerosis-associated pulmonary arterial hypertension. Ann Rheum Dis. 2008;67(8):1121–1126. doi:10.1136/ard.2007.080424
   PubMed Web of Science ®Google Scholar
• Oller-Rodríguez JE, Vicens Bernabeu E, Gonzalez-Mazarío R, Grau García E, Ortiz Sanjuan FM, Román Ivorra JA. Utility of cytokines CXCL4, CXCL8 and GDF15 as biomarkers in systemic sclerosis. Med Clin (Barc). 2022;159(8):359–365. doi:10.1016/j.medcli.2021.12.006
   PubMed Web of Science ®Google Scholar
• Papaioannou AI, Zakynthinos E, Kostikas K, et al. Serum VEGF levels are related to the presence of pulmonary arterial hypertension in systemic sclerosis. BMC Pulm Med. 2009;9(1):18. doi:10.1186/1471-2466-9-18
   PubMedGoogle Scholar
• Silva I, Almeida C, Teixeira A, Oliveira J, Vasconcelos C. Impaired angiogenesis as a feature of digital ulcers in systemic sclerosis. Clin Rheumatol. 2016;35(7):1743–1751. doi:10.1007/s10067-016-3219-8
   PubMed Web of Science ®Google Scholar
• Xu B, Xu G, Yu Y, Lin J. The role of TGF-β or BMPR2 signaling pathway-related miRNA in pulmonary arterial hypertension and systemic sclerosis. Arthritis Res Ther. 2021;23(1):288. doi:10.1186/s13075-021-02678-6
   PubMed Web of Science ®Google Scholar
• Grignaschi S, Sbalchiero A, Spinozzi G, et al. Endoglin and Systemic Sclerosis: a PRISMA-driven systematic review. Front Med. 2022;9:964526. doi:10.3389/fmed.2022.964526
   Web of Science ®Google Scholar
• Odler B, Foris V, Gungl A, et al. Biomarkers for Pulmonary Vascular Remodeling in Systemic Sclerosis: a Pathophysiological Approach. Front Physiol. 2018;9:587. doi:10.3389/fphys.2018.00587
   PubMed Web of Science ®Google Scholar
• Kawashiri SY, Ueki Y, Terada K, Yamasaki S, Aoyagi K, Kawakami A. Improvement of plasma endothelin-1 and nitric oxide in patients with systemic sclerosis by bosentan therapy. Rheumatol Int. 2014;34(2):221–225. doi:10.1007/s00296-013-2861-6
   PubMed Web of Science ®Google Scholar
• Wu Q, Cao F, Tao J, Li X, Zheng SG, Pan HF. Pentraxin 3: a promising therapeutic target for autoimmune diseases. Autoimmun Rev. 2020;19(12):102584. doi:10.1016/j.autrev.2020.102584
   PubMed Web of Science ®Google Scholar
• Kanno Y. The Role of Fibrinolytic Regulators in Vascular Dysfunction of Systemic Sclerosis. Int J Mol Sci. 2019;20(3):619. doi:10.3390/ijms20030619
   PubMed Web of Science ®Google Scholar
• Giannelli G, Iannone F, Marinosci F, Lapadula G, Antonaci S. The effect of bosentan on matrix metalloproteinase-9 levels in patients with systemic sclerosis-induced pulmonary hypertension. Curr Med Res Opin. 2005;21(3):327–332. doi:10.1185/030079905X30680
   PubMed Web of Science ®Google Scholar
• Manetti M, Guiducci S, Romano E, et al. Increased serum levels and tissue expression of matrix metalloproteinase-12 in patients with systemic sclerosis: correlation with severity of skin and pulmonary fibrosis and vascular damage. Ann Rheum Dis. 2012;71(6):1064–1072. doi:10.1136/annrheumdis-2011-200837
   PubMed Web of Science ®Google Scholar
• Romano E, Manetti M, Rosa I, et al. Slit2/Robo4 axis may contribute to endothelial cell dysfunction and angiogenesis disturbance in systemic sclerosis. Ann Rheum Dis. 2018;77(11):1665–1674. doi:10.1136/annrheumdis-2018-213239
   PubMed Web of Science ®Google Scholar
• Yokoyama K, Mitoma H, Kawano S, et al. CEACAM 1, 3, 5 and 6 -positive classical monocytes correlate with interstitial lung disease in early systemic sclerosis. Front Immunol. 2022;13:1016914. doi:10.3389/fimmu.2022.1016914
   PubMed Web of Science ®Google Scholar
• Pellicano C, Iannazzo F, Romaggioli L, Rosato E. IL33 and sST2 serum level in systemic sclerosis microvascular involvement. Microvasc Res. 2022;142:104344. doi:10.1016/j.mvr.2022.104344
   PubMed Web of Science ®Google Scholar
• Kolstad KD, Khatri A, Donato M, et al. Cytokine signatures differentiate systemic sclerosis patients at high versus low risk for pulmonary arterial hypertension. Arthritis Res Ther. 2022;24(1):39. doi:10.1186/s13075-022-02734-9
   PubMed Web of Science ®Google Scholar
• Jiang Z, Chen C, Yang S, He H, Zhu X, Liang M. Contribution to the peripheral vasculopathy and endothelial cell dysfunction by CXCL4 in Systemic Sclerosis. J Dermatol Sci. 2021;104(1):63–73. doi:10.1016/j.jdermsci.2021.07.006
   PubMed Web of Science ®Google Scholar
• Ichimura Y, Asano Y, Akamata K, et al. Fli1 deficiency contributes to the suppression of endothelial CXCL5 expression in systemic sclerosis. Arch Dermatol Res. 2014;306(4):331–338. doi:10.1007/s00403-013-1431-9
   PubMed Web of Science ®Google Scholar
• Iannone F, Praino E, Rotondo C, et al. Body mass index and adipokines/cytokines dysregulation in systemic sclerosis. Clin Exp Immunol. 2021;206(2):153–160. doi:10.1111/cei.13651
   PubMed Web of Science ®Google Scholar
• Korman BD, Marangoni RG, Hinchcliff M, et al. Brief Report: association of Elevated Adipsin Levels With Pulmonary Arterial Hypertension in Systemic Sclerosis. Arthritis Rheumatol. 2017;69(10):2062–2068. doi:10.1002/art.40193
   PubMed Web of Science ®Google Scholar
• Sawicka K, Michalska-Jakubus M, Potembska E, Kowal M, Pietrzak A, Krasowska D. Visfatin and chemerin levels correspond with inflammation and might reflect the bridge between metabolism, inflammation and fibrosis in patients with systemic sclerosis. Postepy Dermatol Alergol. 2019;36(5):551–565. doi:10.5114/ada.2018.79104
   PubMed Web of Science ®Google Scholar
• Bălănescu P, Lădaru A, Bălănescu E, Nicolau A, Băicuş C, Dan GA. IL-17, IL-6 and IFN-γ in Systemic Sclerosis Patients. Rom J Intern Med. 2015;53(1):44–49. doi:10.1515/rjim-2015-0006
   PubMedGoogle Scholar
• Sun C, Zhu H, Wang Y, et al. Serum metabolite differences detected by HILIC UHPLC-Q-TOF MS in systemic sclerosis. Clin Rheumatol. 2023;42(1):125–134. doi:10.1007/s10067-022-06372-z
   PubMed Web of Science ®Google Scholar
• Long H, Wang X, Chen Y, Wang L, Zhao M, Lu Q. Dysregulation of microRNAs in autoimmune diseases: pathogenesis, biomarkers and potential therapeutic targets. Cancer Lett. 2018;428:90–103. doi:10.1016/j.canlet.2018.04.016
   PubMed Web of Science ®Google Scholar
• Zhang Y, Qin D, Qin L, Yang X, Luo Q, Wang H. Diagnostic value of cardiac natriuretic peptide on pulmonary hypertension in systemic sclerosis: a systematic review and meta-analysis. Joint Bone Spine. 2022;89(2):105287. doi:10.1016/j.jbspin.2021.105287
   PubMed Web of Science ®Google Scholar
• Pagkopoulou E, Soulaidopoulos S, Katsiki N, et al. The role of asymmetric dimethylarginine in endothelial dysfunction and abnormal nitric oxide metabolism in systemic sclerosis: results from a pilot study. Clin Rheumatol. 2023;42(4):1077–1085. doi:10.1007/s10067-022-06472-w
   PubMed Web of Science ®Google Scholar
• Pagkopoulou E, Soulaidopoulos S, Triantafyllidou E, et al. Asymmetric dimethylarginine correlates with worsening peripheral microangiopathy in systemic sclerosis. Microvasc Res. 2023;145:104448. doi:10.1016/j.mvr.2022.104448
   PubMed Web of Science ®Google Scholar
• Xanthouli P, Gordjani O, Benjamin N, et al. Hypochromic red cells as a prognostic indicator of survival among patients with systemic sclerosis screened for pulmonary hypertension. Arthritis Res Ther. 2023;25(1):38. doi:10.1186/s13075-023-03020-y
   PubMed Web of Science ®Google Scholar
• Chikhoune L, Brousseau T, Morell-Dubois S, et al. Association between Routine Laboratory Parameters and the Severity and Progression of Systemic Sclerosis. J Clin Med. 2022;11(17):5087. doi:10.3390/jcm11175087
   PubMed Web of Science ®Google Scholar
• Kayser C, Fritzler MJ. Autoantibodies in systemic sclerosis: unanswered questions. Front Immunol. 2015;6:167. doi:10.3389/fimmu.2015.00167
   PubMed Web of Science ®Google Scholar
• Lomelí-Nieto JA, Muñoz-Valle JF, Baños-Hernández CJ, et al. Transforming growth factor beta isoforms and TGF-βR1 and TGF-βR2 expression in systemic sclerosis patients. Clin Exp Med. 2022;23(2):471–481. doi:10.1007/s10238-022-00841-0
   PubMed Web of Science ®Google Scholar
• Isomura Y, Shirai Y, Kuwana M. Clinical worsening following discontinuation of tocilizumab in diffuse cutaneous systemic sclerosis: a single-centre experience in Japan. Rheumatology. 2022;61(11):4491–4496. doi:10.1093/rheumatology/keac136
   PubMed Web of Science ®Google Scholar
• Lescoat A, Roofeh D, Kuwana M, et al. Therapeutic Approaches to Systemic Sclerosis: recent Approvals and Future Candidate Therapies. Clin Rev Allergy Immunol. 2023;64(3):239–261. doi:10.1007/s12016-021-08891-0
   PubMed Web of Science ®Google Scholar
• Stifano G, Sornasse T, Rice LM, et al. Skin Gene Expression Is Prognostic for the Trajectory of Skin Disease in Patients With Diffuse Cutaneous Systemic Sclerosis. Arthritis Rheumatol. 2018;70(6):912–919. doi:10.1002/art.40455
   PubMed Web of Science ®Google Scholar
• Clark KEN, Csomor E, Campochiaro C, et al. Integrated analysis of dermal blister fluid proteomics and genome-wide skin gene expression in systemic sclerosis: an observational study. Lancet Rheumatol. 2022;4(7):e507–e516. doi:10.1016/S2665-9913(22)00094-7
   PubMedGoogle Scholar
• Gordon JK, Martyanov V, Franks JM, et al. Belimumab for the Treatment of Early Diffuse Systemic Sclerosis: results of a Randomized, Double-Blind, Placebo-Controlled, Pilot Trial. Arthritis Rheumatol. 2018;70(2):308–316. doi:10.1002/art.40358
   PubMed Web of Science ®Google Scholar
• Wirz EG, Jaeger VK, Allanore Y, et al. Incidence and predictors of cutaneous manifestations during the early course of systemic sclerosis: a 10-year longitudinal study from the EUSTAR database. Ann Rheum Dis. 2016;75(7):1285–1292. doi:10.1136/annrheumdis-2015-207271
   PubMed Web of Science ®Google Scholar
• Kuwana M, Allanore Y, Denton CP, et al. Nintedanib in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease: subgroup Analyses by Autoantibody Status and Modified Rodnan Skin Thickness Score. Arthritis Rheumatol. 2022;74(3):518–526. doi:10.1002/art.41965
   PubMed Web of Science ®Google Scholar
• Namas R, Tashkin DP, Furst DE, et al. Efficacy of Mycophenolate Mofetil and Oral Cyclophosphamide on Skin Thickness: post Hoc Analyses From Two Randomized Placebo-Controlled Trials. Arthritis Care Res. 2018;70(3):439–444. doi:10.1002/acr.23282
   PubMed Web of Science ®Google Scholar
• Johnson SR, Feldman BM, Pope JE, Tomlinson GA. Shifting our thinking about uncommon disease trials: the case of methotrexate in scleroderma. J Rheumatol. 2009;36(2):323–329. doi:10.3899/jrheum.071169
   PubMed Web of Science ®Google Scholar
• Roden AC, Camus P. Iatrogenic pulmonary lesions. Semin Diagn Pathol. 2018;35(4):260–271. doi:10.1053/j.semdp.2018.03.002
   PubMed Web of Science ®Google Scholar
• Karalilova RV, Batalov ZA, Sapundzhieva TL, Matucci-Cerinic M, Batalov AZ. Tofacitinib in the treatment of skin and musculoskeletal involvement in patients with systemic sclerosis, evaluated by ultrasound. Rheumatol Int. 2021;41(10):1743–1753. doi:10.1007/s00296-021-04956-7
   PubMed Web of Science ®Google Scholar
• Khanna D, Denton CP, Furst DE, et al. A 24-Week, Phase IIa, Randomized, Double-blind, Placebo-controlled Study of Ziritaxestat in Early Diffuse Cutaneous Systemic Sclerosis (NOVESA). Arthritis Rheumatol. 2023. doi:10.1002/art.42477
   Google Scholar
• Kuzumi A, Ebata S, Fukasawa T, et al. Long-term Outcomes After Rituximab Treatment for Patients With Systemic Sclerosis: follow-up of the DESIRES Trial With a Focus on Serum Immunoglobulin Levels. JAMA Dermatol. 2023;159(4):374–383. doi:10.1001/jamadermatol.2022.6340
   PubMed Web of Science ®Google Scholar
• Ebata S, Oba K, Kashiwabara K, et al. Predictors of rituximab effect on modified Rodnan skin score in systemic sclerosis: a machine-learning analysis of the DesiReS trial. Rheumatology. 2022;61(11):4364–4373. doi:10.1093/rheumatology/keac023
   PubMed Web of Science ®Google Scholar
• Frech TM, Frech M, Saknite I, et al. Novel therapies and innovation for systemic sclerosis skin ulceration. Best Pract Res Clin Rheumatol. 2023;4:101813. doi:10.1016/j.berh.2022.101813
   Google Scholar
• Davuluri S, Lood C, Chung L. Calcinosis in systemic sclerosis. Curr Opin Rheumatol. 2022;34(6):319–327. doi:10.1097/BOR.0000000000000896
   PubMed Web of Science ®Google Scholar
• Touart DM, Sau P. Cutaneous deposition diseases. Part I. J Am Acad Dermatol. 1998;39(2 Pt 1):149–171. doi:10.1016/S0190-9622(98)70069-6
   PubMed Web of Science ®Google Scholar
• Herrick AL. Raynaud’s phenomenon and digital ulcers: advances in evaluation and management. Curr Opin Rheumatol. 2021;33(6):453–462. doi:10.1097/BOR.0000000000000826
   PubMed Web of Science ®Google Scholar
• Flavahan NA. New mechanism-based approaches to treating and evaluating the vasculopathy of scleroderma. Curr Opin Rheumatol. 2021;33(6):471–479. doi:10.1097/BOR.0000000000000830
   PubMed Web of Science ®Google Scholar
• Volkmann ER, McMahan Z. Gastrointestinal involvement in systemic sclerosis: pathogenesis, assessment and treatment. Curr Opin Rheumatol. 2022;34(6):328–336. doi:10.1097/BOR.0000000000000899
   PubMed Web of Science ®Google Scholar
• Khanna D, Hays RD, Maranian P, et al. Reliability and validity of the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument. Arthritis Rheum. 2009;61(9):1257–1263. doi:10.1002/art.24730
   PubMedGoogle Scholar
• Lafyatis R, Valenzi E. Assessment of disease outcome measures in systemic sclerosis. Nat Rev Rheumatol. 2022;18(9):527–541. doi:10.1038/s41584-022-00803-6
   PubMed Web of Science ®Google Scholar
• Hamberg V, Wallman JK, Mogard E, Lindqvist E, Olofsson T, Andréasson K. Elevated fecal levels of the inflammatory biomarker calprotectin in early systemic sclerosis. Rheumatol Int. 2023;43(5):961–967. doi:10.1007/s00296-022-05264-4
   PubMedGoogle Scholar
• Ebrahimi B, Nazarinia M, Molayem M. Calprotectin, an available prognostic biomarker in systemic sclerosis: a systematic review. Clin Rheumatol. 2021;40(5):1709–1715. doi:10.1007/s10067-020-05446-0
   PubMed Web of Science ®Google Scholar
• Cole A, Ong VH, Denton CP. Renal Disease and Systemic Sclerosis: an Update on Scleroderma Renal Crisis. Clin Rev Allergy Immunol. 2023;64(3):378–391. doi:10.1007/s12016-022-08945-x
   PubMed Web of Science ®Google Scholar
• Clark KE. Review of systemic sclerosis and antineutrophil cytoplasmic antibody vasculitis overlap: using autoantibodies for a personalised medicine approach. J Scleroderma Relat Disord. 2023;8(1):7–13. doi:10.1177/23971983221126850
   PubMed Web of Science ®Google Scholar
• Chew E, Barnado A, Ikizler TA, Zent R, Frech T. Evaluation of hypertension in systemic sclerosis and systemic lupus erythematosus overlap. J Scleroderma Relat Disord. 2023;8(1):14–19. doi:10.1177/23971983221122673
   PubMed Web of Science ®Google Scholar
• Bose N, Chiesa-Vottero A, Chatterjee S. Scleroderma renal crisis. Semin Arthritis Rheum. 2015;44(6):687–694. doi:10.1016/j.semarthrit.2014.12.001
   PubMed Web of Science ®Google Scholar
• Denton CP, Sweny P, Abdulla A, Black CM. Acute renal failure occurring in scleroderma treated with cyclosporin A: a report of three cases. Br J Rheumatol. 1994;33(1):90–92. doi:10.1093/rheumatology/33.1.90
   PubMedGoogle Scholar
• Tonsawan P, Talabthong K, Puapairoj A, Foocharoen C. Renal pathology and clinical associations in systemic sclerosis: a historical cohort study. Int J Gen Med. 2019;12:323–331. doi:10.2147/IJGM.S221471
   PubMed Web of Science ®Google Scholar
• Hudson M, Baron M, Tatibouet S, Furst DE, Khanna D. International Scleroderma Renal Crisis Study Investigators. Exposure to ACE inhibitors prior to the onset of scleroderma renal crisis-results from the International Scleroderma Renal Crisis Survey. Semin Arthritis Rheum. 2014;43(5):666–672. doi:10.1016/j.semarthrit.2013.09.008
   PubMed Web of Science ®Google Scholar
• Steen VD, Mayes MD, Merkel PA. Assessment of kidney involvement. Clin Exp Rheumatol. 2003;21(3 Suppl 29):S29–31.
   PubMed Web of Science ®Google Scholar
• Berger M, Steen VD. Role of anti-receptor autoantibodies in pathophysiology of scleroderma. Autoimmun Rev. 2017;16(10):1029–1035. doi:10.1016/j.autrev.2017.07.019
   PubMed Web of Science ®Google Scholar
• Nagaraja V. Management of scleroderma renal crisis. Curr Opin Rheumatol. 2019;31(3):223–230. doi:10.1097/BOR.0000000000000604
   PubMed Web of Science ®Google Scholar
• Hoa S, Stern EP, Denton CP, Hudson M; Scleroderma Clinical Trials Consortium Scleroderma Renal Crisis Working Group Investigators of the Scleroderma Clinical Trials Consortium Scleroderma Renal Crisis Working Group. Towards developing criteria for scleroderma renal crisis: a scoping review. Autoimmun Rev. 2017;16(4):407–415. doi:10.1016/j.autrev.2017.02.012
   PubMed Web of Science ®Google Scholar
• Okrój M, Johansson M, Saxne T, Blom AM, Hesselstrand R. Analysis of complement biomarkers in systemic sclerosis indicates a distinct pattern in scleroderma renal crisis. Arthritis Res Ther. 2016;18(1):267. doi:10.1186/s13075-016-1168-x
   PubMedGoogle Scholar
• Osthoff M, Jaeger VK, Heijnen IAFM, et al. Role of lectin pathway complement proteins and genetic variants in organ damage and disease severity of systemic sclerosis: a cross-sectional study. Arthritis Res Ther. 2019;21(1):76. doi:10.1186/s13075-019-1859-1
   PubMedGoogle Scholar
• Shimizu K, Ogawa F, Yoshizaki A, et al. Increased serum levels of soluble CD163 in patients with scleroderma. Clin Rheumatol. 2012;31(7):1059–1064. doi:10.1007/s10067-012-1972-x
   PubMed Web of Science ®Google Scholar
• Yanaba K, Asano Y, Tada Y, et al. Increased serum soluble CD147 levels in patients with systemic sclerosis: association with scleroderma renal crisis. Clin Rheumatol. 2012;31(5):835–839. doi:10.1007/s10067-012-1949-9
   PubMed Web of Science ®Google Scholar
• Fonseca C, Renzoni E, Sestini P, et al. Endothelin axis polymorphisms in patients with scleroderma. Arthritis Rheum. 2006;54(9):3034–3042. doi:10.1002/art.22036
   PubMedGoogle Scholar
• Penn H, Quillinan N, Khan K, et al. Targeting the endothelin axis in scleroderma renal crisis: rationale and feasibility. QJM. 2013;106(9):839–848. doi:10.1093/qjmed/hct111
   PubMed Web of Science ®Google Scholar
• Stratton RJ, Coghlan JG, Pearson JD, et al. Different patterns of endothelial cell activation in renal and pulmonary vascular disease in scleroderma. QJM. 1998;91(8):561–566. doi:10.1093/qjmed/91.8.561
   PubMed Web of Science ®Google Scholar
• Chighizola CB, Pregnolato F, Meroni PL, Denton CP, Ong VH. N-terminal pro Brain Natriuretic Peptide as predictor of outcome in scleroderma renal crisis. Clin Exp Rheumatol. 2016;34 Suppl 100(5):122–128.
   PubMed Web of Science ®Google Scholar
• Penn H, Howie AJ, Kingdon EJ, et al. Scleroderma renal crisis: patient characteristics and long-term outcomes. QJM. 2007;100(8):485–494. doi:10.1093/qjmed/hcm052
   PubMed Web of Science ®Google Scholar
• Tormey VJ, Bunn CC, Denton CP, Black CM. Anti-fibrillarin antibodies in systemic sclerosis. Rheumatology. 2001;40(10):1157–1162. doi:10.1093/rheumatology/40.10.1157
   PubMed Web of Science ®Google Scholar
• Codullo V, Cavazzana I, Bonino C, et al. Serologic profile and mortality rates of scleroderma renal crisis in Italy. J Rheumatol. 2009;36(7):1464–1469. doi:10.3899/jrheum.080806
   PubMed Web of Science ®Google Scholar
• Merashli M, Alves J, Ames PRJ. Clinical relevance of antiphospholipid antibodies in systemic sclerosis: a systematic review and meta-analysis. Semin Arthritis Rheum. 2017;46(5):615–624. doi:10.1016/j.semarthrit.2016.10.004
   PubMed Web of Science ®Google Scholar
• Ogawa F, Shimizu K, Hara T, et al. Autoantibody against one of the antioxidant repair enzymes, methionine sulfoxide reductase A, in systemic sclerosis: association with pulmonary fibrosis and vascular damage. Arch Dermatol Res. 2010;302(1):27–35. doi:10.1007/s00403-009-0996-9
   PubMed Web of Science ®Google Scholar
• Clements PJ, Lachenbruch PA, Furst DE, Maxwell M, Danovitch G, Paulus HE. Abnormalities of renal physiology in systemic sclerosis. A prospective study with 10-year followup. Arthritis Rheum. 1994;37(1):67–74. doi:10.1002/art.1780370110
   PubMedGoogle Scholar
• Gigante A, Barbano B, Barilaro G, et al. Serum uric acid as a marker of microvascular damage in systemic sclerosis patients. Microvasc Res. 2016;106:39–43. doi:10.1016/j.mvr.2016.03.007
   PubMed Web of Science ®Google Scholar
• Reiseter S, Molberg Ø, Gunnarsson R, et al. Associations between circulating endostatin levels and vascular organ damage in systemic sclerosis and mixed connective tissue disease: an observational study. Arthritis Res Ther. 2015;17(1):231. doi:10.1186/s13075-015-0756-5
   PubMedGoogle Scholar
• Akamata K, Asano Y, Taniguchi T, et al. Increased expression of chemerin in endothelial cells due to Fli1 deficiency may contribute to the development of digital ulcers in systemic sclerosis. Rheumatology. 2015;54(7):1308–1316. doi:10.1093/rheumatology/keu479
   PubMed Web of Science ®Google Scholar
• Takahashi T, Asano Y, Noda S, et al. A possible contribution of lipocalin-2 to the development of dermal fibrosis, pulmonary vascular involvement and renal dysfunction in systemic sclerosis. Br J Dermatol. 2015;173(3):681–689. doi:10.1111/bjd.13779
   PubMed Web of Science ®Google Scholar
• Aozasa N, Asano Y, Akamata K, et al. Serum apelin levels: clinical association with vascular involvements in patients with systemic sclerosis. J Eur Acad Dermatol Venereol. 2013;27(1):37–42. doi:10.1111/j.1468-3083.2011.04354.x
   PubMed Web of Science ®Google Scholar
• Pawlik KK, Bohdziewicz A, Chrabąszcz M, et al. Biomarkers of disease activity in systemic sclerosis. Wiad Lek. 2020;73(10):2300–2305. doi:10.36740/WLek202010137
   PubMedGoogle Scholar
• Akamata K, Asano Y, Noda S, et al. An inverse correlation of serum angiogenin levels with estimated glomerular filtration rate in systemic sclerosis patients with renal dysfunction. Eur J Dermatol. 2013;23(2):269–270. doi:10.1684/ejd.2013.1924
   PubMed Web of Science ®Google Scholar
• Żółkiewicz J, Stochmal A, Rudnicka L. The role of adipokines in systemic sclerosis: a missing link? Arch Dermatol Res. 2019;311(4):251–263. doi:10.1007/s00403-019-01893-1
   PubMed Web of Science ®Google Scholar
• Stern EP, Unwin R, Burns A, Ong VH, Denton CP. Exploring molecular pathology of chronic kidney disease in systemic sclerosis by analysis of urinary and serum proteins. Rheumatol Adv Pract. 2021;5(1):rkaa083. doi:10.1093/rap/rkaa083
   PubMedGoogle Scholar